IS VACCINATION RELATED TO THE CURE RATE OF COVID-19 PATIENTS WITH COMORBIDITIES?

by Mia Herdiyani Achmad

IS VACCINATION RELATED TO THE CURE RATE OF COVID-19 PATIENTS WITH COMORBIDITIES?

Mia Herdiyani Achmad, Reviono, Yusup Subagio Sutanto, Jatu Aphridasari, Windu Prasetyo

Pulmonology and Respiratory Medicine

Medical Faculty of Sebelas Maret University/ Dr. Moewardi General Hospital Surakarta

Abstract

Introduction: Vaccination can prevent a COVID-19 patient from falling into moderate, severe, and critical conditions. The effect of vaccination on COVID-19 patients' recovery has been widely studied. However, its correlation in critically severe COVID-19 patients with comorbidity has not been fully understood yet.

Objective: To determine the correlation of vaccination in critically severe COVID-19 patients with comorbidity of hypertension and/or Diabetes Mellitus (DM).

Methods: A retrospective cohort study was conducted in critically severe COVID-19 patients with hypertension and/or DM treated in Dr. Moewardi Hospital, Surakarta, Indonesia from March 2021 to September 2021. The data were taken from patients' medical records. We analyzed all data statistically with Chi-Square and fisher's exact test, and a p-value of < 0.05 was considered significant.

Results: There were 489 patients included in our study, 247 patients with hypertention and DM, and 242 patients without comorbidities. Vaccination status was significantly associated with the cure rate of critically severe COVID-19 patients with hypertension (p=0.018), but not with DM (p=0.606). There was no significant association between age to the cure rate of critically severe COVID-19 patients with hypertension and DM (p=0.953). Vaccination status was related among patients with comorbidities and without comorbidities (p<0.001).

Conclusion: Vaccination was significantly correlated the cure rate of moderate to critically severe COVID-19 patients with hypertension and without comorbidities.

Keywords: COVID-19, vaccination, hypertension, diabetes, cure rate

BACKGROUND

The World Health Organization (WHO) has declared COVID-19 as a pandemic since March 11, 2020.[1] Its clinical manifestations are diverse ranging from asymptomatic to fatal complications, such as acute respiratory distress syndrome (ARDS) and respiratory failure.[1,2] The common comorbidities are hypertension (15.6%), diabetes mellitus (7.7%), and cardiovascular disease (4.7%). Approximately 44.5% diabetes patiens and 41,7% hypertension patients are included in critical cases. Research in Indonesia stated that hypertension, diabetes mellitus (DM), and cardiovascular disease are the most common comorbids, which then related to the severity of symptoms. However, its role in mortality and treatment's duration has not widely known yet.[3,4,5] Various attempts have been made to develop SARS-CoV-2 vaccines in recent decades.[3] The SARS-CoV-2 antigen vaccine can prevent COVID-19 infection and/or minimize its morbidity.[6] This study aimed to determine the relationship between COVID-19 vaccination and the recovery of moderate, severe, and critical COVID-19 patients with comorbid factors.

MATERIAL AND METHODS

The study was a retrospective cohort, by taking medical records of moderate, severe, and critical COVID-19 patients undergoing intensive care in the isolation room from 1st March to 30th September 2021 at dr. Moewardi Hospital, Surakarta. The sample size was measured using the total purposive sampling. The inclusion criteria were adult patients more than 18 years old, patients with hypertension and/or DM, patients without comorbidities, patients with a history of vaccination, patients undergoing treatment in isolation rooms with confirmed moderate, severe, and critical COVID-19 cases, and a patient who underwent laboratory examination (GDP, G2PP, HbA1C, D dimer). Exclusion criteria were patients with absent or incomplete medical records and non-confirmed COVID-19. It was approved by the Ethics Feasibility Committee of the RSDM / Faculty of Medicine, Sebelas Maret University, Surakarta in January 2022 with the ethical approval number 26/I/HREC/2022. The data was statistically analyzed using SPSS version 25.0. Kolmogorov-Smirnov Test was used to determine the normality. The hypothesis test was Chi-Square/Fischer's Exact Test. The confidence interval was 95%. P-value< 0.05 was declared as statistically significant relationship.

RESULT

This study analyzed 489 moderate, severe, and critical COVID-19 patients undergoing treatment in Melati 1 isolation room at Dr. RSUD. Moewardi Surakarta from 1st March to 30th September 2021. Among them, 247 patients have hypertension and/DM and 242 patients have no comorbidities.

The median value of patients' age was 47 (18- 87) years old. The patients were mostly female accounted for 320 patients (65.4%). In this study, there were 248 patients (50.7%) who had not been vaccinated against COVID-19, 34 patients had received the 1st vaccine (7.0%), and 207 patients had undergone 2nd vaccine (42.3%). There were 89 patients with hypertension (18.2%), 99 patients with DM (20.2%), and 59 patients hypertension and DM (12.1%). Patients with death outcomes were 220 patients (45.0%) and living outcomes were 269 patients (55.5%) (See table 1).

Based on age, patients who died tended to be older than those who lived. The median age of patients with comorbid hypertension and DM was 61 (19-87) years who died and 58 (19-79) years who lived. There was no significant difference (p = 0.953) in the age of died or lived patients. In patients with comorbid hypertension and DM and no history of vaccines, 85,6% were died and 14.4% were alive. While in patients with 1st vaccine and 2nd dose vaccines, death occurred in 85,7% and 67,7% were patients, respectively. There was a significant relationship (p = 0.043) between vaccination status in moderate, severe, and critical COVID-19 patients with comorbid on their recovery. Around 88,9% patients with comorbid hypertension complicated with DM who have not been vaccinated was dying. Death occurred in patients with the 1st dose and 2nd dose were 80.0% and 55.6%,

respectively. It means that the vaccination status of moderate, severe, and critical COVID-19 patients with comorbid factors of both hypertension and DM was not significantly correlated with its recovery (p = 0.051)

Table 1. Characteristics of subjects

Characteristics	Result (n=489)
Age (years)	47 (18- 87)
Gender	
Male	169 (34.6%)
Female	320 (65.4%)
Vaccine Status	
No vaccine	248 (50.7%)
1st vaccine	34 (7.0%)
2nd vaccine	207 (42.3%)
Comorbid	
Hypertension	89 (18.2%)
DM	99 (20.2%)
Hypertension and DM	59 (12.1%)
Without comorbidities	242 (49.5%)
Outcome	
Death	220 (45.0%)
Alive	269 (55.0%)

It was known that good outcome (alive) were mostly patients with 2nd vaccine without comorbidities counted as 98.3%. It also had higher cure rate up to 32.3%. There was a significant relationship (p=<0.001) between vaccination status of moderate, severe, and critical COVID-19 patients with comorbid factors and no comorbidity to its outcome (see table 2).

Table 2. The correlation between vaccination status of moderate, severe, and critical COVID-19 patients and the outcome

	N	Die	Alive	p-value
Vaccination status	489			<0.001*
1st Vaccine with HT dan DM	21	18 (85.7%)	3 (14.3%)	
1st Vaccine without comorbidities	13	3 (23.1%)	10 (76.9%)	
2nd Vaccine with HT dan DM	31	21 (67.7%)	10 (32.3%)	
2nd Vaccine without comorbidities	176	3 (1.7%)	173 (98.3%)	
No Vaccine with HT dan DM	195	167 (85.6%)	28 (14.4%)	
No Vaccine without comorbidities	53	8 (15.1%)	45 (84.9%)	

Note: *chi square*:* significant at p<0,05, HT= hypertension, DM= diabetes mellitus

It was also known that patients who had good outcome (alive) were mostly patients without comorbidities counted as 94.2%, while who had bad outcome (die) were mostly patients with comorbid hypertension and DM counted as 83.4%. There was a significant

relationship (p=<0.001) between comorbid factors (no comorbidities of moderate, severe, and critical COVID 19 patients with the recovery outcome (see table 3).

Table 3. The correlation between comorbidities of moderate, severe, and critical COVID-19 patients and the outcome

	N	Die	Alive	p-value
Comorbidities				<0.001*
With comorbidities HT and/or DM	247	206 (83.4%)	41 (16.6%)	
Without comorbidities	242	14 (5.8%)	228 (94.2%)	

Note: *chi square/fisher exact test* :*significant at p<0,05, HT= hypertension, DM= diabetes mellitus

The survival rate of patients with hypertension and DM who had not been vaccinated was only 14.4%. The survival rate of patients who were vaccinated with the 1st dose and 2nd dose were 14.3% and 32.3%, respectively. Vaccination status was significantly related to the recovery of moderate, severe, and critical COVID-19 patients with comorbid hypertension and/or DM (p value = 0.043). On the other hand, the survival rate of patients with hypertension who have not been vaccinated was 13.2%. In patients with the 1st dose and 2nd dose vaccine, the survival rate were 0% and 41.7%, respectively. The vaccination status was significantly related to the recovery status of moderate, severe, and critical COVID-19 patients with hypertension (p value = 0.018) (see table 4).

Table 4. The correlation between vaccination status of moderate, severe, and critical COVID-19 patients with comorbidities and the outcome

	N	Die	Alive	p-value
Vaccination (All Comorbidities)	247			0.043*
No Vaccine	195	167 (85.6%)	28 (14.4%)	
1st Vaccine	21	18 (85.7%)	3 (14.3%)	
2nd Vaccine	31	21 (67.7%)	10 (32.3%)	
Age (Hypertension)	89			0.018*
No Vaccine	68	59 (86.8%)	9 (13.2%)	
1st Vaccine	9	9 (100.0%)	0 (0.0%)	
2nd Vaccine	12	7 (58.3%)	5 (41.7%)	
Age (DM)	99			0.606
No Vaccine	82	68 (82.9%)	14 (17.1%)	
1st Vaccine	7	5 (71.4%)	2 (28.6%)	
2nd Vaccine	10	9 (90.0%)	1 (10.0%)	
Age (DM+Hypertension)	59			0.051
No Vaccine	45	40 (88.9%)	5 (11.1%)	
1st Vaccine	5	4 (80.0%)	1 (20.0%)	
2nd Vaccine	9	5 (55.6%)	4 (44.4%)	

Note: *chi square*:*significant at p<0,05

Table 5. The correlation between age and vaccination status of moderate, severe, and critical COVID-19 patients with comorbidities and the outcome

	N	Die (year)	Alive (year)	p-value
Age (All Comorbidities)[a]	247	61 (19-87)	58 (19-79)	0.327
Age (Hypertension)[a]	89	60.28 +13.13	60.93 +10.25	0.862
No Vaccine [a]	68	59.59 +13.18	57.44 +9.28	0.640
1st Vaccine [b]	9	61.89 +12.08	-	-
2nd Vaccine [a]	12	64.00 +15.11	67.20 +9.63	0.687
Age (DM)[a]	99	60.68 +9.72	55.82 +12.96	0.080
No Vaccine [a]	82	60.09 +10.01	55.07 +13.15	0.110
1st Vaccine [b]	7	63 (52-63)	52 (46-68)	0.228
2nd Vaccine [b]	10	65 (54-78)	74 (74-74)	0.384
Age (DM+Hypertension)[a]	59	61.47+8.77	67.40 +7.97	0.982
No Vaccine [a]	45	61.40 +9.09	58.40 +8.96	0.490
1st Vaccine [b]	5	62 (56-72)	67 (67-67)	0.480
2nd Vaccine [a]	9	60.80+8.93	63.75+7.14	0.609

Note: [a] Uji *mann whitney*; [b] uji *independent t test*:*significant at p<0,05

Table 5 showed that patients who died tended to be older than those who lived. It could be seen that the median age of patients with comorbid hypertension and DM was 61 (19-87) years, while the median age of patients living was 58 (19-79) years (p = 0.953). The average age of COVID 19 patients with comorbid hypertension who died was 60.28 +13.13 years, while those who lived was 60.93 +10.25 years (p = 0.862). Based their vaccination status, there was no significant difference in patients who had not been vaccinated (p=0.640), received 1st dose (p=-), and 2nd dose (p=0.687). The average age of patients with comorbid DM who died was 60.68 +9.72 years, while those who lived was 55.82 +12.96 years (p = 0.080). Based their vaccination status, there was no significant difference in patients who had not been vaccinated (p = 0.110), received 1st dose (p = 0.228), and 2nd dose (p=0.384). The average age of COVID 19 patients with comorbid hypertension complicated with DM who died was 61.47+8.77 years, while those who lived was 67.40+7.97 years (p = 0.982). Based their vaccination status, there was no significant difference in patients who had not been vaccinated (p=0.490), received 1st dose (p=0.480), and 2nd dose (p=0.609). There was no significant relationship between age and vaccination status in moderate, severe, and critical COVID-19 patients with or without comorbidities on its recovery.

DISCUSSION

Caifang, et al., 2021; Gili, et al., 2022 proved that COVID-19 vaccination can prevent the severity of COVID-19. Sowmya, et al., 2021 stated patients without comorbidities and had been vaccinated showed better recovery. Christian, et al., 2021 concluded that vaccination in hypertension patient required more research to determine the effectiveness.

This study found that there was a significant relationship between vaccination and recovery in moderate to critical COVID-19 patients with comorbid factors (hypertension and

diabetes mellitus) and without comorbidities (p = <0.001). It was known that good outcome (alive) were mostly patients with 2nd vaccine without comorbidities counted as 98.3%, while bad outcome (die) was mostly those with comorbidities who had not been vaccinated yet (85.6%) or only received the 1st vaccine (85.7%).

Hypertension is strongly correlated with lower antibodies. There is a similar mechanism of immune dysfunction in hypertension and vaccination's inappropriate response. Hypertension was previously found to be correlated with worse outcomes, suggesting higher morbidity as well as mortality in COVID-19 infection, and thus may be involved in the development of an immunologic response to vaccination.[7,8]

The prevalence of DM in COVID-19 patients ranges from 8.2% to 10.3%. In several studies, the presence of DM in COVID-19 was stated as an independent factor associated with severity and increased mortality. A meta-analysis of 33 studies concluded that DM in COVID-19 was associated with a twofold increased risk of death and disease severity, compared to patients without DM.[9]

The success of vaccination can be seen in COVID-19 patients without comorbidities as its cure rate was better than patients with comorbidities. It was also shown that 94.2% patients without comorbidities stayed alive, while 83.4% patients with comorbid hypertension and DM died (p value = <0.001). Irawaty, et al., 2021, stated that patients with comorbid hypertension and DM had a lower cure rate than those without comorbidities which was aligned with our study.

SARS-CoV-2 vaccination mostly targets glycoprotein or protein S as the main inducer of antibodies. The S protein-based vaccines induce antibodies that block both the viral receptor binding and the uncoating viral genome. The C-terminal domain of the S1 subunit of the coronavirus delta represents a dominant immune region. This region exhibits the strongest neutralization. Protein S has known to have a big role in promoting protective immunity during SARS-CoV2 infection by inducting antibodies and T-cell. Glycoprotein S is believed to be the most promising candidate for CoV vaccine composition. Other structural proteins affect the immunogenicity of protein S or ACE2 receptor-binding which is an important initial step for viruses to access to host cells. Both RBD-containing recombinant protein and RBD-encoding recombinant vector have superior abilities to induce neutralizing antibodies which can be used to develop an effective SARS-CoV vaccine.[8,9,10]

This research found vaccination status was significantly related to the recovery of moderate, severe, and critical COVID-19 patients with comorbid hypertension and/or DM (p value = 0.043) and with hypertension only (p value = 0.018). Patients with 2nd dose vaccine had a higher cure rate than patients with 1st dose and who had not been vaccinated yet. The vaccination triggers a memory immune response that eliminates the SARS-CoV-2 virus and improves its clinical outcomes in hypertensive patients. The ACE2 converts angiotensin II to angiotensin I-VII to neutralize the inflammatory effects of angiotensin II,

reduce the level of pro-inflammatory cytokine interleukin 6, increase the anti-inflammatory and antioxidant role of angiotensin I-VII, increase the concentration of alveolar surfactant protein D, and induce vasodilation.[11,12]

On the other hand, the vaccination was not significantly correlated in DM patients (p=0.606) or in patients with complications of hypertension with DM (p = 0.051). The results of this study are not in line with previous studies that showed an impaired antibody response to influenza and hepatitis B vaccines in DM patient. Recent studies showed people with DM can enhance an appropriate immune response post-vaccination. Several case-control studies showed that the effectiveness and safety of the pneumococcal vaccine ranged from 56% to 81%. The effectiveness of the 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) was 84% in people with DM. The PPV23 effectively prevents pneumococcal disease and reduces the utilization of medical services in patients aged 75 years old or older with DM. Young and elderly adults with DM have been shown to promote an optimal B cell responses to seasonal influenza vaccine. [13-16]

Based on the existing theory, DM causes glucotoxicity and endothelial damage due to the inflammation, oxidative stress. Thereby, thromboembolic complication increases putting organ vitals in a high risk of malfunction. Microangiopathy in DM may also reduce the lung compliance which in turn will interfere air exchange in the lungs. There are also some changes in respiratory in DM patients that affect lung volume and lung diffusion capacity. DM and hypertension are chronic inflammations that further exacerbate the dysfunction of T cells, dendritic cells and other inflammatory factors.[16,17] Blood sugar control also affects the mortality of COVID-19 patients with DM, as in a study of 10,926 on COVID-19 which concluded that there was an increased risk of death in patients with poor HbA1c. A multicenter retrospective research in China also found that one of independent factors of mortality in COVID-19 patients was the high fasting glucose levels at admission (≥7.0 mmol/l OR 126 mg/dl)). DM was associated with the risk of COVID-19 with severe symptoms including the risk of ARDS, use of the ICU room, and the need for a ventilator.[13,15]

All age groups are at risk of being infected with COVID-19. Based on the research, it was known that patients who died tended to be older than those who lived, even though the data was not significantly correlated (p = 0.953). An epidemiological analysis showed that 77.8% of COVID-19 patients were in the age range of 30 to 69 years with the highest proportion in the age of 50 to 60 years. The infection rate in children was considered as relatively low. High severity happens in patients aged >60 years old, living in nursing homes or long-term care facilities, and had chronic diseases. Male patient dominated counted as 56.9% cases. The highest mortality rate happens in patients aged >70 years old, regardless of the presence of a chronic medical condition, such as 32% od cardiovascular disease, 30% of DM, and 18% of chronic lung disease. Other conditions that put people at high risk were cancer, obesity, kidney disease, sickle cell disease, and other immunocompromised

conditions.[2,18-20]

There were some limitations of the study. First, it was a retrospective cohort research in which observations were made indirectly by relying on medically recorded data only. Thus, we could not control the data quality. In addition, indirect observations made it difficult to accurately determine the effective time of the vaccine. Second, this study did not rule out the type and the onset of the vaccine. The effect of antibodies after its administration might affect the outcome of moderate, severe, and critical COVID-19 patients. Research with a longer period is also required to determine the development of the subject's condition and diagnosis.

CONCLUSIONS

Vaccination, especially the 2nd dose, was significantly associated with the cure rate of moderate to critically severe COVID-19 patients with hypertension and without comorbidities. Hence, it is important to diagnosis a controlled hypertension early. Further prospective research is needed on the type of COVID-19 vaccines to see the success rate of vaccination in people with comorbidities.

REFERENCES

1. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. World Health Organization., Geneva: World Health Organization; 2020 [cited 2021 Jan 31]. Available from: www.who.int

2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID- 19) Treatment Guidelines [Internet]. National Institutes of Health. 2020 [cited 2021 Jan 31]. Available from: https://www.covid19treatmentguidelines.nih.gov/

3. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta- analysis. Journal of clinical virology.2020;1(1):1-7.

4. Karyono D, Wicaksana A. No Title. J community Empower Heal. 2020;3(2).

5. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al. Features ofsevere COVID-19: Asystematic reviewand meta-analysis. Eur JClin Invest. 2020;50(10):1–7.

6. Adnan M, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin ,transmission, and characteristics of human coronaviruses. J Adv Res [Internet]. 2020;24:91–8. Available from: https://doi.org/10.1016/j.jare.2020.03.005

7. Sun SH, Chen Q, Gu HJ et al. A Mouse Model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124–33.

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. Lancet Infect Dis. 2020;395:497–506.

9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323:1061–1069.

10. Zhang X, Yu J, Pan L, Jiang H. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta- analysis. Pharmacol Res [Internet]. 2020;158(May):104927. Available from: https://doi.org/10.1016/j.phrs.2020.104927

11. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect the company's public news and information . 2020;(January).

12. Rossi G, Sanga V, Barton M. No Title. Elife. 2020;9(e57278).

13. Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes, Obes Metab. 2020;22(10):1915–24.

14. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol - Endocrinol Metab. 2020;318(5):736–41.

15. Rao S, Lau A, So H. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes- Related Traits. Diabetes CCare. 2020;43(7):1416–26.

16. Fernandez C, Rysa J, Almgren P, Nilsson J. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284:377–87.

17. Lim S, Bae J., Kwon H., Nauck M. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11– 30.

18. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematicreview and meta-analysis. Int J Infect Dis. 2020;94:91–5.

19. Stokes EK, Zambrano LD, Anderson KN et al. Coronavirus disease 2019 case surveillance — United States, January 22–May 30, 2020 [Internet]. 2020. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6924e2-H.pdf.

20. Zhang Z, Hou Y, Li D, Li F. Laboratory findings of COVID-19 : asystematic review and meta-analysis. Scand J Clin Lab Invest. 2020;1:1–7.

IS VACCINATION RELATED TO THE CURE RATE OF COVID-19 PATIENTS WITH COMORBIDITIES?

1	files.covid19treatmentguidelines.nih.gov Internet Source	2%
2	bmcinfectdis.biomedcentral.com Internet Source	1%
3	www.researchsquare.com Internet Source	1%
4	platcovid.com Internet Source	1%
5	www.wjgnet.com Internet Source	1%
6	Hooman Aghamirza Moghim Aliabadi, Reza Eivazzadeh‐Keihan, Arezoo Beig Parikhani, Sara Fattahi Mehraban et al. "COVID‐19: A systematic review and update on prevention, diagnosis, and treatment", MedComm, 2022 Publication	1%
7	"Poster Presentation - Asthma : Abstract", Respirology, 2014. Publication	1%

8 www.tandfonline.com
Internet Source
1 %

9 www.medrxiv.org
Internet Source
<1 %

10 Submitted to Imperial College of Science, Technology and Medicine
Student Paper
<1 %

11 digilib.uns.ac.id
Internet Source
<1 %

12 Letícia Martins Raposo, Gabriel Ferreira Diaz Abreu, Felipe Borges de Medeiros Cardoso, André Thiago Jonathas Alves et al. "Symptom-based clusters of hospitalized patients with Severe Acute Respiratory Illness by SARS-CoV-2 in Brazil", Journal of Infection and Public Health, 2022
Publication
<1 %

13 Y. Lian, Y. Tian. "The Clinical Study of the Effect of WBRT on Cognitive Function of Patients With Brain Metastasis of Lung Cancer", International Journal of Radiation Oncology*Biology*Physics, 2021
Publication
<1 %

14 Saleh A Alqahtani, Maria Buti. "COVID-19 and Hepatitis B Infection", Antiviral Therapy, 2019
Publication
<1 %

15   Volker Tschuschke, Margit Koemeda-Lutz, Agnes von Wyl, Aureliano Crameri, Peter Schulthess. "The Impact of Clients' and Therapists' Characteristics on Therapeutic Alliance and Outcome", Journal of Contemporary Psychotherapy, 2021
Publication

<1 %

16   ejournal.undip.ac.id
Internet Source

<1 %

17   www.degruyter.com
Internet Source

<1 %

18   www.ncbi.nlm.nih.gov
Internet Source

<1 %

19   Ghaffar Shokouhi, Mohammad Asghari, Moslem Shakeri, Neda Sattarnezhad, Atta Mahdkhah, Farid Panahi. "Pedicle Screw Fixation at the Level of the Fracture", Neurosurgery Quarterly, 2015
Publication

<1 %

20   repository.usu.ac.id
Internet Source

<1 %

21   Yicheng Yang, Zhiqiang Xiao, Kaiyan Ye, Xiaoen He, Bo Sun, Zhiran Qin, Jianghai Yu, Jinxiu Yao, Qinghua Wu, Zhang Bao, Wei Zhao. "SARS-CoV-2: characteristics and current advances in research", Virology Journal, 2020
Publication

<1 %

22 moam.info
Internet Source
<1%

23 Wojciech Dabrowski, Mariusz Gagos, Dorota Siwicka-Gieroba, Mariusz Piechota et al. "Humulus lupus extract rich in Xanthohumol reduces the risk of a fatal clinical course in critically ill patients treated for COVID-19", Research Square Platform LLC, 2022
Publication
<1%

24 dergipark.org.tr
Internet Source
<1%

25 spotidoc.com
Internet Source
<1%

26 Adree Khondker, Jethro CC Kwong, Christopher Tran, Emily Evans et al. "Incidence of dural metastases in castrate-resistant prostate cancer", Journal of Clinical Urology, 2022
Publication
<1%

27 Deepak Dhamnetiya, Pankaj Kumar, Shelesh Kumar Goel, Abhinav Jha, Apoorv Amitabh Bharatwal, Saurabh Singh, Ravi Prakash Jha. "Adverse Events Following Immunization of ChAdOx1 nCoV- 19 Vaccine Among Health Care Workers of a Tertiary Care Hospital of North India", Research Square Platform LLC, 2022
<1%

28 Larissa Gomes Barbosa, Artur Christian Garcia Silva, Juliana Marques Oliveira, Mary Hellen Fabres Klein et al. "S100A9 as an inflammatory marker in hospitalized COVID-19 patients", Research Square Platform LLC, 2022
Publication

<1%

29 Muhammad Fachri, Mochammad Hatta, Evelin Widowati, Risky Akaputra et al. "Correlations between comorbidities, chest x-ray findings, and C-Reactive protein level in patients with COVID-19", Annals of Medicine and Surgery, 2022
Publication

<1%

30 Yao Zhou, Zipeng Liu, Hongxi Yang, Jianhua Wang, Tong Liu, Kexin Chen, Yaogang Wang, Pak Chung Sham, Ying Yu, Mulin Jun Li. "Coagulation factors and COVID-19 severity: Mendelian randomization analyses and supporting evidence", Cold Spring Harbor Laboratory, 2020
Publication

<1%

31 assets.researchsquare.com
Internet Source

<1%

32 covidreference.com
Internet Source

<1%

33 ejournal2.undip.ac.id
    Internet Source   <1%

34 jcp.semnan.ac.ir
    Internet Source   <1%

35 journal.wima.ac.id
    Internet Source   <1%

36 mmrjournal.biomedcentral.com
    Internet Source   <1%

37 pubannotation.org
    Internet Source   <1%

38 www.frontiersin.org
    Internet Source   <1%

39 www.nepjol.info
    Internet Source   <1%

40 Sebastião Freitas de Medeiros, Márcia Marly
    Winck Yamamoto, Matheus Antônio Souto de   <1%
    Medeiros, Ana Karine Lin Winck Yamamoto et
    al. "Polycystic ovary syndrome and risks for
    COVID-19 infection: A comprehensive review",
    Reviews in Endocrine and Metabolic
    Disorders, 2022
    Publication

41 Hamideh Amirfakhryan, Fatemeh safari.
    "Outbreak of SARS-CoV2: Pathogenesis of   <1%

| Exclude quotes | Off | | Exclude matches | Off |
| Exclude bibliography | On | | | |

IS VACCINATION RELATED TO THE CURE RATE OF COVID-19 PATIENTS WITH COMORBIDITIES?

FINAL GRADE

/1

GENERAL COMMENTS

Instructor